Cognivia launches the world’s first real-time behavioral risk intelligence dashboard—Cognivia Signal—empowering clinical teams to see what’s coming before it happens.
Mont-Saint-Guibert, Belgium – October 9, 2025 – Cognivia, the AI-driven leader in behavioral science for clinical research, proudly announces the launch of Cognivia Signal, a groundbreaking solution designed to transform how clinical trial sponsors manage behavioral risk.
Cognivia Signal is the first platform of its kind to provide real-time visibility into the behavioral and contextual drivers of trial participants. By identifying early signs of dropout risk, nonadherence, and placebo response, the dashboard enables sponsors to take proactive action—before it’s too late.
“The reasons for patient dropout and placebo response are rooted in complex behavior,” said Dr. Bert Hartog, former Senior Director Clinical Innovation at J&J. “Cognivia Signal provides access to data that helps sponsors proactively manage some of the biggest hurdles faced in clinical development.”
Why It Matters
Clinical trials are increasingly challenged by high dropout rates and placebo effects—two of the most costly and disruptive factors in drug development. Cognivia Signal addresses these challenges head-on by:
- Pinpointing dropout risk—who is likely to leave, where, and why
- Detect behavioral drivers behind placebo response
In a recent Type 1 Diabetes trial, Cognivia Signal predicted 93% of participant dropouts, flagging them as high-risk before they exited the study.
“This is a step toward behavior-informed clinical research,” said Chantal Gossuin, Chief Operating Officer at Cognivia. “Understanding the human factors behind trial data should be standard practice—and now it can be.”
Cognivia Signal joins Placebell and Compl-AI as the third product in Cognivia’s suite of behavioral intelligence tools, reinforcing the company’s mission to reduce behavioral variability and improve trial outcomes.